Effect of antithrombotic therapy in patients with mitral stenosis and atrial fibrillation: A sub-analysis of NASPEAF randomized trial

European Heart Journal

Volumn 27, Issue 8, 2006, Pages 960-967

  Pérez Gómez, Francisco ^a   Salvador, Antonio ^b   Zumalde, Javier ^c   Iriarte, Jose A ^d   Berjón, Jésus ^e   Alegría, Eduardo ^f   Almería, Carlos ^a   Bover, Ramón ^a   Herrera, Dionisio ^g   Fernández, Cristina ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^c HOSPITAL DE GALDAKAO   (Spain)

^d HOSPITAL DE BASURTO   (Spain)

^e Universidad Pública de Navarra   (Spain)

^f UNIVERSITY CLINIC OF NAVARRA   (Spain)

^g Centro Medico Avenida Portugal ^*  (Spain)

Author keywords

Anticoagulants; Antiplatelets; Atrial fibrillation; Mitral stenosis; Severe bleeding; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; PROSTAGLANDIN SYNTHASE INHIBITOR; TRIFLUSAL;

ADULT; AGED; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE DISEASE; MITRAL VALVE STENOSIS; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; STROKE; SURVIVAL RATE; THROMBOEMBOLISM; THROMBOSIS PREVENTION; TREATMENT OUTCOME;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; CEREBROVASCULAR ACCIDENT; DEATH, SUDDEN, CARDIAC; DRUG COMBINATIONS; EMBOLISM; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; MALE; MITRAL VALVE STENOSIS; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; TREATMENT OUTCOME;

EID: 33645511293     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehi667     Document Type: Article

References (22)

1. Szekely P. Systemic embolism and anticoagulant prophylaxis in rheumatic heart disease. BMJ 1964;5392:1209-1212.
2. Adams GF, Merret JD, Hutchinson WM, Pollock AM. Cerebral embolism and mitral stenosis. Survival with and without anticoagulants. J Neurosurg Psychiatry 1974;37:378-383.
3. Fleming HA, Bailay SM. Mitral valve disease, systemic embolism and anticoagulation. Postgrad Med J 1971;47:599-604.
4. Deverall PB, Olley PM, Smith DR, Watson DA, Whitaker W. Incidence of embolism before and after mitral valvotomy. Thorax 1968;23:530-536.
5. Levine HJ. Which atrial fibrillation patients should be on chronic anti-coagulation? J Cardiovasc Med 1981;6:483-487.
6. Loeliger EA, Poller L, Samama M, Thomson JM, Van den Besselaar AM, Vermylen J, Verstrase M. Questions and answers on prothrombin time standardisation in oral anticoagulant control. Thromb Haemost 1985;54:515-517.
7. Fuster V, Ryden LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, Halperin JL, Kay GN, Klein WW, Levy S, McNamara RL, Prystowsky EN, Wann LS, Wyse DG. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Eur Heart J 2001;22:1852-1923.
8. British Society for Haematology, British Committee for Standards in Haematology and Haemostasis and Thrombosis Task Force. Guidelines on oral anticoagulation. 2nd ed. J Clin Pathol 1990;43:685-690.
9. Salen DN, Levine HJ, Panker SG, Eckman MH, Daudelin DH. Antithrombotic therapy in valvular heart disease. Chest 1998;114:590-601.
10. Singer DE, Albers GW, Dalen JE, Go AS, Halperin JL, Mannning WJ. Antithrombotic therapy in atrial fibrillation. The 7th ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:4295-4565.
11. Pengo V, Barbero F, Biasiolo A, Pegoraro C, Noventa F, Lliceto S. Prevention of thromboembolism in patients with mitral stenosis and associated atrial fibrillation: effectiveness of low intensity (INR target 2) oral anticoagulation treatment. Thromb Haemost 2003;89:760-764.
12. Perez-Gomez F, Alegria E, Berjon J, Iriarte JA, Zumalde J, Salvador A, for the NASPEAF Investigators. Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation. A randomised study. J Am Coll Cardiol 2004;44:1557-1566.
13. McNeely W, Goa KL. Triflusal. Drugs 1998;55:823-833.
14. Cruz-Fernandez JM, Lopez-Bescos L, Garcia-Dorado D, Lopez Garcia-Aranda V, Cabades A, Martín-Jadraque L, Velasco JA, Castro-Beiras A, Torres F, Marfil F, Navarro E. Randomised comparative trial of triflusal and aspirin following acute myocardial infarction. Eur Heart J 2000;21:457-465.
15. Matías-Guiu J, Ferro JM, Alvarez-Sabín J, Torres F, Jimenez MD, Lago A, Melo T. Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction. The TACIP study: a randomised, double blind, multicenter trial. Stroke 2003;34:840-848.
16. Oden A, Fahlen M, Hart R. Optimal INR for prevention of stroke and death in atrial fibrillation: a critical appraisal. Thromb Res 2005, in press.
17. van Walraven C, Hart RG, Singer DE, Laupacis A, Connolly S, Petersen P, Koudstaal PJ, Chang Y, Hellemons B. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation. JAMA 2002;288:2441-2448.
18. Stroke Prevention in Atrial Fibrillation III Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: stroke prevention in atrial fibrillation III randomised clinical trial. Lancet 1996;348:633-638.
19. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischemic attack or minor stroke. Lancet 1993;342:1255-1262.
20. Schafer AI. The primary and secondary hypercoagulable states. In: Schafer AI, ed. Molecular Mechanisms of Hypercoagulable States. Landes Bioscience: Austin; 1997. p1-48.
21. Fatkin D, Kelly RP, Feneley MP, Feneley MP. Relations between left atrial appendage blood flow velocity, spontaneous echocardiographic contrast and thromboembolic risk in vivo. J Am Coll Cardiol 1994;23:961-969.
22. Rastegar R, Harnich DJ, Weidemann P, Fuster V, Coller B, Badimon JJ, Chesebro J, Goldman ME. Spontaneous echo contrast videodensity is flow-related and is dependent on the relative concentrations of fibrinogen and red blood cells. J Am Coll Cardiol 2003;41:603-610.